Earnings Outlook: Gilead earnings: Expect a strong quarter despite executive turnover

After struggling with sluggish sales for Gilead Sciences Inc.’s core products, executives have been calling 2018 a “trough year.”

This quarter could be make or break — and Leerink Partners analyst Geoffrey Porges is betting on the former.

While many large biotechnology companies have seen prescriptions decline compared with the prior year, Gilead’s GILD, -1.37% prescription volumes have actually grown, Porges said.

The Wall Street analyst, who rates Gilead as market perform, predicts that the company will have top-line and bottom-line beats this quarter.

Gilead has had declining growth for onetime powerhouse hepatitis C and HIV franchises in recent quarters.

>>> Original Source <<<